JP2008545000A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545000A5
JP2008545000A5 JP2008519857A JP2008519857A JP2008545000A5 JP 2008545000 A5 JP2008545000 A5 JP 2008545000A5 JP 2008519857 A JP2008519857 A JP 2008519857A JP 2008519857 A JP2008519857 A JP 2008519857A JP 2008545000 A5 JP2008545000 A5 JP 2008545000A5
Authority
JP
Japan
Prior art keywords
ccr7 receptor
cell
tumor cells
cells
ccr7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008519857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545000A (ja
JP5249025B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2005/007371 external-priority patent/WO2007003216A1/en
Application filed filed Critical
Publication of JP2008545000A publication Critical patent/JP2008545000A/ja
Publication of JP2008545000A5 publication Critical patent/JP2008545000A5/ja
Application granted granted Critical
Publication of JP5249025B2 publication Critical patent/JP5249025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008519857A 2005-07-06 2006-07-05 ガンを治療するための抗ccr7受容体抗体 Active JP5249025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
EPPCT/EP2005/007371 2005-07-06
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2008545000A JP2008545000A (ja) 2008-12-11
JP2008545000A5 true JP2008545000A5 (enExample) 2009-11-12
JP5249025B2 JP5249025B2 (ja) 2013-07-31

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519857A Active JP5249025B2 (ja) 2005-07-06 2006-07-05 ガンを治療するための抗ccr7受容体抗体

Country Status (16)

Country Link
US (1) US8066996B2 (enExample)
EP (1) EP1904102B1 (enExample)
JP (1) JP5249025B2 (enExample)
KR (1) KR20080030655A (enExample)
CN (1) CN101257923A (enExample)
AT (1) ATE453407T1 (enExample)
AU (1) AU2006265281C1 (enExample)
BR (1) BRPI0612632A2 (enExample)
CA (1) CA2614080C (enExample)
DE (1) DE602006011466D1 (enExample)
DK (1) DK1904102T3 (enExample)
ES (1) ES2338919T3 (enExample)
IL (1) IL188594A (enExample)
PT (1) PT1904102E (enExample)
RU (1) RU2404808C2 (enExample)
WO (2) WO2007003216A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5315495B2 (ja) * 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトccr7抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2014151834A2 (en) * 2013-03-15 2014-09-25 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
JP6618191B2 (ja) * 2014-03-27 2019-12-11 国立研究開発法人医薬基盤・健康・栄養研究所 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
HUE051920T2 (hu) 2015-08-10 2021-03-29 Pepmab B V Humanizált, CCR7 receptor elleni antitestek
EA201890908A1 (ru) 2015-10-09 2018-10-31 Сарепта Терапьютикс, Инк. Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US20220064311A1 (en) * 2018-12-18 2022-03-03 Catapult Therapeutics B.V. The use of anti-CCR7 mabs for the prevention or treatment of graft-versus-host disease (GvHD)
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
JP5049011B2 (ja) * 2003-06-11 2012-10-17 ザ ユニバーシティー オブ シカゴ 変異体lightによるt細胞腫瘍浸潤の増大

Similar Documents

Publication Publication Date Title
JP2008545000A5 (enExample)
Barkauskas et al. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis
Pishas et al. Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response
FR2936102B1 (fr) Procede de preparation d'un materiau composite silicium/ carbone, materiau ainsi prepare et electrode notamment electrode negative, comprenant ce materiau.
RU2008104420A (ru) Антитела против рецептора ccr7 для лечения рака
JP2006006329A5 (enExample)
JP2010505386A5 (enExample)
JP2011502333A5 (enExample)
JP2004115529A5 (enExample)
JP2008515616A5 (enExample)
JP2009537552A5 (enExample)
JP2007522094A5 (enExample)
JP2010538767A5 (enExample)
ECSP099404A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
JP2009545657A5 (enExample)
JP2014098004A5 (enExample)
JP2008245635A5 (enExample)
JP2014519258A5 (enExample)
JP2011525000A5 (enExample)
JP2016527891A5 (enExample)
TWD119910S1 (zh) 晶舟
AR069554A1 (es) Compuesto triciclico de amino benzoimidazol
JP2009536926A5 (enExample)
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
JP2012515773A5 (enExample)